DURECT Corp. (DRRX:NASDAQ) announced in a news release that results from its Phase 2a clinical trial of DUR-928 in alcoholic hepatitis (AH) were delivered in an oral presentation at The Liver Meeting by Dr. Tarek Hassanein, one of the study's principal investigators.
Further, the biopharmaceutical company today hosted a key opinion leader webcast with slides in which Hassanein again presented the data and answered questions.
"The results of this study are remarkable and much was learned from this Phase 2a clinical trial," Hassanein said in the release. "The low Lille scores, the early reduction in bilirubin and the number of severe AH patients who were able to be discharged after a single dose of DUR-928 is striking, and the safety profile looks very promising as well."
Next, DURECT intends to conduct a double-blind, placebo-controlled, Phase 2b clinical trial evaluating DUR-928 in AH patients. This is expected to start in mid-2020 and have topline data available in 2022.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: DURECT. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
